Trending NewsTrending NewsNASDAQ:AUPH Aurinia Pharmaceuticals (AUPH) Stock Price, News & Analysis $10.49 +1.25 (+13.53%) Closing price 08/1/2025 04:00 PM EasternExtended Trading$10.42 -0.08 (-0.71%) As of 08/1/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Aurinia Pharmaceuticals Stock (NASDAQ:AUPH) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get AUPH alerts:Sign Up Key Stats Today's Range$9.33▼$10.5250-Day Range$7.47▼$10.4952-Week Range$5.20▼$10.67Volume7.74 million shsAverage Volume1.95 million shsMarket Capitalization$1.42 billionP/E Ratio24.40Dividend YieldN/APrice Target$12.00Consensus RatingBuy Company Overview Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. It offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. The company was incorporated in 1993 and is headquartered in Edmonton, Canada. Read More Aurinia Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks46th Percentile Overall ScoreAUPH MarketRank™: Aurinia Pharmaceuticals scored higher than 46% of companies evaluated by MarketBeat, and ranked 757th out of 919 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion2.5 / 5Analyst RatingBuy Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAurinia Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Aurinia Pharmaceuticals' stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth409.09% Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow by 409.09% in the coming year, from $0.11 to $0.56 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is 24.40, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 28.09.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is 24.40, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.67.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 3.91. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted8.91% of the float of Aurinia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently increased by 6.09%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted8.91% of the float of Aurinia Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAurinia Pharmaceuticals has a short interest ratio ("days to cover") of 7.Change versus previous monthShort interest in Aurinia Pharmaceuticals has recently increased by 6.09%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.60 News SentimentAurinia Pharmaceuticals has a news sentiment score of 0.60. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 21 news articles for Aurinia Pharmaceuticals this week, compared to 4 articles on an average week.Search InterestOnly 18 people have searched for AUPH on MarketBeat in the last 30 days. This is a decrease of -44% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Aurinia Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of -33% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Insiders12.20% of the stock of Aurinia Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 36.83% of the stock of Aurinia Pharmaceuticals is held by institutions.Read more about Aurinia Pharmaceuticals' insider trading history. Receive AUPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aurinia Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address AUPH Stock News HeadlinesWhat is HC Wainwright's Estimate for AUPH Q2 Earnings?3 hours ago | americanbankingnews.comAurinia Pharmaceuticals Inc. (NASDAQ:AUPH) Q2 2025 Earnings Call TranscriptAugust 1 at 11:51 AM | msn.comA new rule goes live in July — and the banks are quietly crushing itA little-known regulation quietly goes into effect this July. And it's already being exploited by Wall Street and the Big Banks… It gives them the green light to treat a certain tangible asset as equivalent to cold, hard cash. Not stocks. Not real estate. And definitely not the U.S. dollar. We're talking about something they don't want you to notice — because the fewer people who act on this, the better it is for them. | American Alternative (Ad)Aurinia Pharmaceuticals Inc (AUPH) Q2 2025 Earnings Call Highlights: Strong Revenue Growth and ...August 1 at 4:20 AM | gurufocus.comQ2 2025 Aurinia Pharmaceuticals Inc Earnings Call TranscriptAugust 1 at 3:31 AM | gurufocus.comAurinia (AUPH) Q2 Revenue Jumps 22%July 31 at 10:30 PM | fool.comAurinia Pharmaceuticals Inc. (AUPH) Q2 2025 Earnings Call TranscriptJuly 31 at 6:23 PM | seekingalpha.comAurinia Pharmaceuticals Reports Strong Q2 2025 Financial Results and Expands Share Repurchase PlanJuly 31 at 3:47 PM | msn.comSee More Headlines AUPH Stock Analysis - Frequently Asked Questions How have AUPH shares performed this year? Aurinia Pharmaceuticals' stock was trading at $8.98 on January 1st, 2025. Since then, AUPH shares have increased by 16.8% and is now trading at $10.49. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) posted its quarterly earnings results on Thursday, July, 31st. The biotechnology company reported $0.16 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.17 by $0.01. The biotechnology company had revenue of $70.01 million for the quarter, compared to analyst estimates of $64.27 million. Aurinia Pharmaceuticals had a trailing twelve-month return on equity of 19.57% and a net margin of 23.31%. Read the conference call transcript. Who are Aurinia Pharmaceuticals' major shareholders? Top institutional investors of Aurinia Pharmaceuticals include Nordea Investment Management AB (0.26%), IFP Advisors Inc (0.19%), VIRGINIA RETIREMENT SYSTEMS ET Al (0.08%) and Public Employees Retirement System of Ohio (0.02%). Insiders that own company stock include Peter Greenleaf, Matthew Maxwell Donley, Joseph M Miller, Scott Michael Habig, Stephen P Robertson, Greg Keenan, David RW Jayne, Jeffrey Allen Bailey and Joseph P Hagan. View institutional ownership trends. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Aurinia Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Netflix (NFLX), JPMorgan Chase & Co. (JPM) and Intel (INTC). Company Calendar Last Earnings7/31/2025Today8/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:AUPH CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Fax250-744-2498Employees300Year FoundedN/APrice Target and Rating Average Price Target for Aurinia Pharmaceuticals$12.00 High Price Target$17.00 Low Price Target$9.00 Potential Upside/Downside+14.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Trailing Twelve Months)$0.28 Trailing P/E Ratio37.46 Forward P/E Ratio95.36 P/E GrowthN/ANet Income$5.75 million Net Margins16.11% Pretax Margin16.91% Return on Equity14.27% Return on Assets9.93% Debt Debt-to-Equity Ratio0.16 Current Ratio5.93 Quick Ratio5.26 Sales & Book Value Annual Sales$235.13 million Price / Sales6.03 Cash Flow$0.36 per share Price / Cash Flow29.34 Book Value$2.68 per share Price / Book3.91Miscellaneous Outstanding Shares135,100,000Free Float118,621,000Market Cap$1.42 billion OptionableOptionable Beta1.16 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:AUPH) was last updated on 8/2/2025 by MarketBeat.com Staff From Our PartnersIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredBuffett to put 90% of his money in this one stock?CPA and CFA says you have WAY too many stocks - just buy these 3 After years working at the biggest accoun...Altimetry | SponsoredHe Called Nvidia at $1.10. Now, He Says THIS Stock Will…The original Magnificent Seven returned 16,894%—turning $7K into $1.18 million. Now, the man who called Nvi...The Oxford Club | SponsoredDigital Dollar Alert: Protect Your Wealth Before It’s Too Late134 countries are developing Central Bank Digital Currencies — and the U.S. is quietly testing one. Experts...American Alternative | SponsoredChina just unlocked Nvidia’s AI chips—what that means for youTired of Missing Big AI Moves Like Nvidia? You’re not the problem—your trading system is. Tim’s XGPT system...Timothy Sykes | SponsoredREVEALED FREE: Our top 3 stocks to own in 2025 and beyondEvery time Weiss Ratings flashed green like this, the average gain on each and every stock has been 303% (incl...Weiss Ratings | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Aurinia Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.